Clinical Trial Update: Effect Of Rilapladib (SB-659032) On Platelet Aggregation [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effect of rilapladib (SB-659032) on platelet aggregation in healthy subjects and individuals with atherosclerosis; the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Rilapladib (rilapladib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Healthy Subjects, Atherosclerosis | Phase 1 | Status: COMPLETED